The ongoing COVID-19 pandemic has been nothing short of a nightmare. As the number of infected patients approaches 400,000, there is already a sense of worry looming across the industries. From disrupted supply chains to a prominent decrease in demand, the pharmaceutical industry is also facing its share of difficulties. A prominent shift towards the virtual clinical trials market has been noticed following this. <\/p>\n\n\n\n
We, at Roots Analysis, have been trying to understand the extent of the impact that the virus is likely to have on the pharmaceutical contract manufacturing market<\/a>. One of the areas that has been deeply impacted by COVID-19 is clinical research. A number of pharmaceutical companies have halted clinic studies<\/a> in recent days.<\/p>\n\n\n\n